Compare Stocks: WHWK, AVTX, CVAC, and SLDB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTX Avalo Therapeutics	$18.84 -2.6%	$19.08	$9.54 ▼ $24.27	$1.01B	0.78	1.14 million shs	191,169 shs
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
SLDB Solid Biosciences	$10.21 -0.7%	$9.28	$3.79 ▼ $11.45	$1.09B	2.44	1.36 million shs	260,008 shs
WHWK Whitehawk Therapeutics	$4.67 -1.0%	$4.28	$1.76 ▼ $5.49	$265.89M	0.81	314,785 shs	86,152 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTX Avalo Therapeutics	+2.06%	-5.89%	+7.15%	+42.10%	+114.41%
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-13.22%
SLDB Solid Biosciences	+4.05%	+5.76%	+28.18%	+41.99%	+89.32%
WHWK Whitehawk Therapeutics	+1.73%	-2.69%	+18.94%	+7.05%	+158.79%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTX Avalo Therapeutics	$18.84 -2.6%	$19.08	$9.54 ▼ $24.27	$1.01B	0.78	1.14 million shs	191,169 shs
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
SLDB Solid Biosciences	$10.21 -0.7%	$9.28	$3.79 ▼ $11.45	$1.09B	2.44	1.36 million shs	260,008 shs
WHWK Whitehawk Therapeutics	$4.67 -1.0%	$4.28	$1.76 ▼ $5.49	$265.89M	0.81	314,785 shs	86,152 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTX Avalo Therapeutics	+2.06%	-5.89%	+7.15%	+42.10%	+114.41%
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-13.22%
SLDB Solid Biosciences	+4.05%	+5.76%	+28.18%	+41.99%	+89.32%
WHWK Whitehawk Therapeutics	+1.73%	-2.69%	+18.94%	+7.05%	+158.79%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTX Avalo Therapeutics	2.86	Moderate Buy	$45.10	139.45% Upside
CVAC CureVac	1.00	Sell	N/A	N/A
SLDB Solid Biosciences	2.83	Moderate Buy	$18.18	78.17% Upside
WHWK Whitehawk Therapeutics	2.63	Moderate Buy	$8.20	75.78% Upside

Current Analyst Ratings Breakdown

Latest WHWK, AVTX, CVAC, and SLDB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$16.00 ➝ $26.00
8/21/2026	SLDB Solid Biosciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$16.00 ➝ $20.00
8/11/2026	AVTX Avalo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/7/2026	AVTX Avalo Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$50.00 ➝ $48.00
8/7/2026	AVTX Avalo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$35.00 ➝ $30.00
7/24/2026	AVTX Avalo Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
7/17/2026	SLDB Solid Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/13/2026	WHWK Whitehawk Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$9.00
7/6/2026	AVTX Avalo Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
6/30/2026	AVTX Avalo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/25/2026	WHWK Whitehawk Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00

(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTX Avalo Therapeutics	$59K	17,120.70	N/A	N/A	$8.37 per share	2.25
CVAC CureVac	$70.74M	14.78	$0.99 per share	4.73	$3.36 per share	1.39
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	$3.49 per share	N/A
WHWK Whitehawk Therapeutics	N/A	N/A	N/A	N/A	$3.21 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTX Avalo Therapeutics	-$78.26M	-$4.37	N/A	N/A	N/A	N/A	-58.03%	-48.22%	11/5/2026 (Estimated)
CVAC CureVac	$175.50M	$0.72	6.47	N/A	N/A	199.92%	-23.03%	-19.09%	N/A
SLDB Solid Biosciences	-$174.32M	-$1.91	N/A	N/A	N/A	N/A	-71.35%	-60.58%	11/2/2026 (Estimated)
WHWK Whitehawk Therapeutics	-$20.60M	-$1.12	N/A	N/A	N/A	N/A	-53.89%	-49.97%	N/A

Latest WHWK, AVTX, CVAC, and SLDB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	AVTX Avalo Therapeutics	-$0.5827	-$0.83	-$0.2473	-$0.83	N/A	N/A
8/6/2026	Q2 2026	SLDB Solid Biosciences	-$0.4624	-$0.38	+$0.0824	-$0.38	N/A	N/A
8/6/2026	Q2 2026	WHWK Whitehawk Therapeutics	-$0.30	-$0.20	+$0.10	-$0.20	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTX Avalo Therapeutics	N/A	N/A	N/A	N/A	N/A
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A
WHWK Whitehawk Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTX Avalo Therapeutics	N/A	19.31	19.31
CVAC CureVac	0.03	3.70	3.69
SLDB Solid Biosciences	N/A	13.82	13.82
WHWK Whitehawk Therapeutics	N/A	17.38	17.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTX Avalo Therapeutics	87.06%
CVAC CureVac	17.26%
SLDB Solid Biosciences	81.46%
WHWK Whitehawk Therapeutics	52.08%

Insider Ownership

Company	Insider Ownership
AVTX Avalo Therapeutics	4.46%
CVAC CureVac	2.15%
SLDB Solid Biosciences	2.66%
WHWK Whitehawk Therapeutics	49.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTX Avalo Therapeutics	40	53.63 million	51.24 million	Not Optionable
CVAC CureVac	880	224.34 million	219.52 million	No Data
SLDB Solid Biosciences	100	107.22 million	104.37 million	Optionable
WHWK Whitehawk Therapeutics	21	57.01 million	28.56 million	N/A

WHWK, AVTX, CVAC, and SLDB Headlines

Recent News About These Companies

Whitehawk Therapeutics to Participate in Upcoming Investor Conferences

September 2 at 8:00 AM | prnewswire.com

Montanova Capital LLC Has $19.69 Million Position in Whitehawk Therapeutics, Inc. $WHWK

September 1 at 6:07 AM | marketbeat.com

What Makes Whitehawk Therapeutics, Inc. (WHWK) a Strong Momentum Stock: Buy Now?

August 28, 2026 | zacks.com

Wall Street Analysts Predict a 47.64% Upside in Whitehawk Therapeutics, Inc. (WHWK): Here's What You Should Know

August 26, 2026 | zacks.com

1,341,394 Shares in Whitehawk Therapeutics, Inc. $WHWK Bought by ADAR1 Capital Management LLC

August 26, 2026 | marketbeat.com

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives $8.20 Consensus PT from Brokerages

August 24, 2026 | americanbankingnews.com

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

August 19, 2026 | marketbeat.com

Whitehawk Therapeutics Inc WHWK

August 14, 2026 | morningstar.comM

TD Cowen Remains a Hold on Whitehawk Therapeutics (WHWK)

August 10, 2026 | theglobeandmail.com

Whitehawk Therapeutics (NASDAQ:WHWK) Rating Increased to Hold at Wall Street Zen

August 8, 2026 | marketbeat.com

Whitehawk Therapeutics (NASDAQ:WHWK) Announces Quarterly Earnings Results, Beats Estimates By $0.10 EPS

August 6, 2026 | marketbeat.com

Whitehawk’s HWK-016 ADC Trial Advances in Tough Ovarian and Endometrial Cancers

August 6, 2026 | tipranks.com

Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

August 6, 2026 | prnewswire.com

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development

July 7, 2026 | businesswire.com

10 Hot Biotech Stocks Under $5 to Buy

June 10, 2026 | insidermonkey.com

Is Whitehawk Therapeutics (WHWK) One Of The Hot Biotech Stocks Under $5 To Buy?

June 10, 2026 | insidermonkey.com

Whitehawk Therapeutics Presents Realâ€‘World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

May 30, 2026 | gurufocus.com

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

May 30, 2026 | prnewswire.com

Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference

May 28, 2026 | prnewswire.com

WHWK Stock Edges Up After Hours: Firm Boosts Pipeline Of Cancer Drugs On The Heels Of Capital Raise

May 21, 2026 | finance.yahoo.com

Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload

May 21, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

WHWK, AVTX, CVAC, and SLDB Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

$18.84 -0.51 (-2.61%)

As of 01:18 PM Eastern

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

CureVac NASDAQ:CVAC

$4.66 0.00 (0.00%)

As of 09/2/2026

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Solid Biosciences NASDAQ:SLDB

$10.20 -0.08 (-0.73%)

As of 01:19 PM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Whitehawk Therapeutics NASDAQ:WHWK

$4.66 -0.05 (-0.96%)

As of 01:18 PM Eastern

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest WHWK, AVTX, CVAC, and SLDB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest WHWK, AVTX, CVAC, and SLDB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

WHWK, AVTX, CVAC, and SLDB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

WHWK, AVTX, CVAC, and SLDB Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

CureVac NASDAQ:CVAC

Solid Biosciences NASDAQ:SLDB

Whitehawk Therapeutics NASDAQ:WHWK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest WHWK, AVTX, CVAC, and SLDB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest WHWK, AVTX, CVAC, and SLDB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

WHWK, AVTX, CVAC, and SLDB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

WHWK, AVTX, CVAC, and SLDB Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

CureVac NASDAQ:CVAC

Solid Biosciences NASDAQ:SLDB

Whitehawk Therapeutics NASDAQ:WHWK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools